Diabetes Metab J.  2022 Jul;46(4):663-664. 10.4093/dmj.2022.0131.

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)

• Kawada T

• KMID: 2531970
• DOI: http://doi.org/10.4093/dmj.2022.0131

Reference

1. Kim HS, Yoon T, Jung CH, Park JY, Lee WJ. Clinical efficacy of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in type 2 diabetes mellitus: real-world study. Diabetes Metab J. 2022; 46:658–62.

2. Premji R, Nylen ES, Naser N, Gandhi S, Burman KD, Sen S. Lipid profile changes associated with SGLT-2 inhibitors and GLP-1 agonists in diabetes and metabolic syndrome. Metab Syndr Relat Disord. 2022. Apr. 22. [Epub]. https://doi.org/10.1089/met.2022.0004 .

3. Baviera M, Genovese S, Lepore V, Colacioppo P, Robusto F, Tettamanti M, et al. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: a real-world study in two Italian cohorts. Diabetes Obes Metab. 2021; 23:1484–95.

4. Wright AK, Carr MJ, Kontopantelis E, Leelarathna L, Thabit H, Emsley R, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care. 2022; 45:909–18.

5. Gomez-Huelgas R, Sanz-Canovas J, Cobos-Palacios L, Lopez-Sampalo A, Perez-Belmonte LM. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: a treatment approach far beyond their glucose-lowering effect. Eur J Intern Med. 2022; 96:26–33.